Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from May 18, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 16, 2026 — +2.1% at the close.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$42.70 – $44.07Entry zone — fair-value band

$44.36Published — price the day we called it

$47.31Target — the price the thesis aimed for

$51.46Peak — highest point inside the window, not a realized return

$45.31Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 43 days.

At window close

+2.1%

realized, from the publication price to the last close inside the window

Peak gain

+16%

peak, from the publication price — not a realized return

S&P 500, same window

+5.4%

SPY over the identical days, dividend-adjusted

Window close

$45.31

last close inside the window, ended August 16, 2026

Peak price

$51.46

peak on July 29, 2026 — not a realized return

Days to target

The thesis — published May 18, 2026

Predicted growth

+8%

over the measurement window

Target price

$47.31

the price the thesis aimed for

Entry zone

$42.70 – $44.07

the fair-value band we waited for

Price at publication

$44.36

published May 18, 2026

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk is seen as a defensive healthcare pick for the next few months. Buybacks, steady diabetes and obesity product demand, and solid profits make the stock more stable in volatile markets. Near-term upside looks limited after mixed results and a mildly extended chart, so expectation is resilience rather than a big short-term jump.

Primary drivers

Share buybacks give direct support to returns
Diabetes and obesity products show steady demand
High profitability cushions against weak near-term upside
Low volatility makes it steadier in choppy markets

How it played out

NVO: target reached in 43 days

Lyra published a short-term thesis for NVO at $44.36, expecting 8% growth toward $47.31. It described the stock as a defensive healthcare pick and expected resilience rather than a large jump. The thesis pointed to share buybacks, steady diabetes and obesity product demand, high profitability, and low volatility.

The target was reached in 43 days. NVO later peaked at $51.46 on July 29, a 16% gain within the window. By August 16, it had fallen back to $45.31, still above the $44.36 publication price. The expected move played out and was exceeded before the window ended.

What happened during the window

On May 22, 2026, Novo Nordisk announced that a European Medicines Agency committee had recommended its Wegovy pill for approval. On August 4, the company reported 7% adjusted sales growth and 11% adjusted operating profit growth at constant exchange rates for the second quarter.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals